PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials
Crossref DOI link: https://doi.org/10.1007/s13277-014-2559-8
Published Online: 2014-09-07
Published Print: 2014-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Francini, Edoardo
Petrioli, Roberto
Rossi, Giulia
Laera, Letizia
Roviello, Giandomenico
Text and Data Mining valid from 2014-09-07